Abiomed, Inc.
http://www.abiomed.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abiomed, Inc.
Stock Watch: Is Johnson & Johnson Edging Away From Pharma?
J&J’s Medtech division outshone pharma while recently launched innovative products contributed minimally: it is to be hoped investors’ reactions to the first set of big pharma Q1 results will not set the tempo for earnings season.
Medtech’s Leading Revenue Earners In 2023: Johnson & Johnson Tops $30bn
Abbott’s weaker rapid diagnostic sales see the erstwhile industry leader slip down the global 2023 medtech rankings, while Johnson & Johnson passes it on the way up on the back of strong external and internal growth.
Medtech’s Leading Revenue Earners In 2023: Johnson & Johnson Tops $30bn
Abbott’s weaker rapid diagnostic sales see the erstwhile industry leader slip down the global 2023 medtech rankings, while Johnson & Johnson passes it on the way up on the back of strong external and internal growth.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Breethe
- preCARDIA, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice